Search

Now showing items 1-10 of 12

A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.

Townsend, W.; Johnson, R. J.; Pottinger, B. T.; Counsell, N.; Smith, P.; Chadwick, H.; Evans, Katy; Wickham, Caroline; Rudin, Claudius E. (Taylor & Francis, 2016-03-22)
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker, D. L.; Naylor, G.; Kruger, A.; Hamilton, Malcolm; Follows, G.; Rule, S. A. (Wiley, 2016-05-16)
This article is currently freely available from the publisher's site (May 2016). Click on the 'Additional Link' above to access the full-text from the publisher's site.
Massive lymphoma arising from the thyroid requiring emergency cardiac pacing.

Thomas, William; Hamilton-Wood, C.; Taylor, A.; Ruell, Jacqueline A. (Wiley, 2013-02)
EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature.

McDonald, Timothy J.; Perry, Mandy; Peake, R.; Pullan, N.; O'Connor, John D.; Shields, Beverley; Knight, Bea A.; Hattersley, Andrew T. (PLoS One, 2012)
C-peptide and insulin measurements in blood provide useful information regarding endogenous insulin secretion. Conflicting evidence on sample stability and handling procedures continue to limit the widespread clinical use ...
Guidelines for the use of platelet transfusions.

Estcourt, L. J.; Birchall, J.; Allard, S.; Bassey, S. J.; Hersey, P.; Kerr, Paul; Mumford, A. D.; Stanworth, S. J.; Tinegate, H. (Wiley, 2016-12-23)
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.

Harrison, C. N.; Mead, A. J.; Panchal, A.; Fox, S.; Yap, C.; Gbandi, E.; Houlton, A.; Alimam, S.; Ewing, J.; Wood, M.; Chen, F.; Coppell, Jason; Panoskaltsis, N.; Knapper, S.; Ali, S.; Hamblin, A.; Scherber, R.; Dueck, A. C.; Cross, N. C. P.; Mesa, R.; McMullin, M. F. (American Society of Hematology, 2017-08-09)
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and leukemia. Patients resistant/intolerant ...
Expert's comment concerning Grand Rounds case entitled "Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation" by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8).

Todd, Anthony (Springer, 2019-01-02)
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease

Heap, Graham; Walker, Gareth; Todd, Anthony; Bewshea, Claire; Heerasing, Neel; Hendy, Peter; Singh, Abhey (JAMA, 2019-02)
Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with ...
A HaemSTAR-led, UK-wide ‘flash-mob’ audit of intravenous immunoglobulin use in immune thrombocytopenia

Kerr, Jonathan; Martin, Abi (Clinical Medicine, 2019-06)
Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.

Tikhonova, I. A.; Hoyle, M. W.; Snowsill, T. M.; Cooper, C.; Varley-Campbell, J. L.; Rudin, Claudius E.; Mujica Mota, R. E. (Springer, 2016-10-17)
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of azacitidine (Celgene) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of acute myeloid ...

Search

Filters